Opportunity

NIH Reporter #5F31AR085992-02

NIAMS Grant for Research on Bone Loss Mechanisms After Spinal Cord Injury

Buyer

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Posted

June 03, 2026

Respond By

June 10, 2026

Identifier

5F31AR085992-02

NAICS

541715

This opportunity from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports research into bone loss mechanisms following spinal cord injury. - Government Buyer: - National Institutes of Health (NIH) - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) - Project Focus: - Investigating sympathetic signaling and norepinephrine as mechanisms for bone loss after spinal cord injury - Research titled 'Sympathetic signaling as a candidate mechanism underlying bone loss after spinal cord injury' - Methods and Technologies: - Utilization of flow cytometry and single-cell RNA sequencing to analyze hematopoietic changes - OEMs and Vendors: - No specific OEMs or vendors are mentioned in the notice - Products/Services Requested: - No specific products, part numbers, or purchase quantities listed - Notable Requirements: - Emphasis on advanced research techniques - No equipment procurement or technical product requirements specified - Award Details: - Total grant award is $38,937 for fiscal year 2026 - NAICS Codes: - 237110 (Water and Sewer Line and Related Structures Construction) - 541330 (Engineering Services)

Description

This NIH grant opportunity focuses on investigating the mechanisms driving bone loss after spinal cord injury (SCI), specifically examining local sympathetic signaling changes as a candidate mechanism. The study will assess the effects of norepinephrine on bone loss at different SCI levels and explore hematopoietic changes using flow cytometry and single-cell RNA sequencing. The project addresses an urgent medical need due to significant bone volume loss within the first two years post-injury. The funding is provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) for fiscal year 2026.

View original listing